This past week, the Biomedical Advanced Research and Development Authority (BARDA) has provided funding for several antibody-related drug development programs. BARDA is a U.S. government agency within the Department of Health and Human Services (HHS) that funds and supports the development of medical countermeasures to protect against public health threats, such as pandemics, bioterrorism, and other emergencies.

These past few weeks, several antibody drug startups have progressed from the pre-seed stage to final funding rounds. In the pre-seed stage, the focus is on early research, often funded by founders, grants, or angel investors. As the company progresses to the seed stage, it seeks additional funding to validate its scientific concept and develop initial prototypes, attracting early-stage venture capital.

Antibody-drug conjugates (ADCs) have revolutionized the landscape of oncology by delivering targeted therapies that minimize damage to healthy cells while maximizing the impact on cancerous tissues. However, researchers and clinicians are now exploring the many therapeutic possibilities of ADCs in treating a variety of non-cancerous conditions such as autoimmune, infectious, neurological, cardiovascular, and metabolic diseases.

Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies.